产碳青霉烯酶广泛耐药铜绿假单胞菌与美国至墨西哥医疗旅游相关(2018-2019年)
研究调查了2018年1月至2019年12月在墨西哥接受择期侵入性医疗操作后45天内分离出VIM-CRPA或CRPA的美国医疗旅游患者。共在18个州识别38例病例,其中31例由外科医生1手术,27例在A机构手术。全基因组测序显示与外科医生1相关的分离株高度相关,且与蒂华纳其他外科医生相关分离株不同。A机构于2019年3月关闭。
要点
- 38例病例分布于18个州,31例由外科医生1手术,其中27例在A机构手术。
- 全基因组测序显示与外科医生1相关的分离株高度相关,与蒂华纳其他外科医生分离株不同。
- A机构于2019年3月关闭。
核心结论
- 美国患者和提供者应认识到医疗旅游后定植或感染美国不常见的高度耐药病原体的风险。
研究设计与样本
- 病例定义为2018年1月至2019年12月在墨西哥接受择期侵入性医疗操作后45天内分离出VIM-CRPA或CRPA的患者。
- 对分离株进行全基因组测序。
主要发现
- 共在18个州识别38例病例。
- 31例由外科医生1手术,其中27例在A机构手术。
- 全基因组测序显示与外科医生1相关的分离株高度相关,且与蒂华纳其他外科医生相关的分离株不同。
临床怎么用
- 美国患者和提供者应认识到医疗旅游后定植或感染美国不常见的高度耐药病原体的风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) producing the Verona integron‒encoded metallo-β-lactamase (VIM) are highly antimicrobial drug-resistant pathogens that are uncommon in the United States. We investigated the source of VIM-CRPA among US medical tourists who underwent bariatric surgery in Tijuana, Mexico. Cases were defined as isolation of VIM-CRPA or CRPA from a patient who had an elective invasive medical procedure in Mexico during January 2018‒December 2019 and within 45 days before specimen collection. Whole-genome sequencing of isolates was performed. Thirty-eight case-patients were identified in 18 states; 31 were operated on by surgeon 1, most frequently at facility A (27/31 patients). Whole-genome sequencing identified isolates linked to surgeon 1 were closely related and distinct from isolates linked to other surgeons in Tijuana. Facility A closed in March 2019. US patients and providers should acknowledge the risk for colonization or infection after medical tourism with highly drug-resistant pathogens uncommon in the United States.
引用
- Kracalik I, Ham DC, McAllister G, et al. Extensively Drug-Resistant Carbapenemase-Producing Pseudomonas aeruginosa and Medical Tourism from the United States to Mexico, 2018-2019. Emerg Infect Dis. 2022. PMID: 34932447. doi:10.3201/eid2801.211880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。